News about Revolution Medicines

Revolution Medicines (RVMD) shares have risen more than 130% following FDA approval in August 2026 of its pancreatic cancer drug Rasonque (daraxonrasib). To turn a $25,000 investment into $1 million, the company would need a market cap of roughly $1.6 trillion, compared with about $1.2 trillion for Eli Lilly. RBC Capital Markets estimates Rasonque's peak annual sales at $11.5 billion, which at the biotech industry's average price-to-sales ratio of 8.4 would imply a market cap near $97 billion. The article says the stock is probably unlikely to reach $1.6 trillion, but it could still deliver market-beating returns for long-term investors if pipeline candidates zoldonrasib and elironrasib win approvals. Billionaire Stanley Druckenmiller's Duquesne Family Office increased its stake by 26.5% in the third quarter of 2026.

Duquesne Family Office, led by billionaire Stanley Druckenmiller, increased its Revolution Medicines stake by 26.5% in the second quarter, before the company's Rasonque won U.S. approval in August for certain pancreatic cancer patients. In a Phase 3 study, Rasonque achieved median overall survival of 13.2 months versus 6.7 months for chemotherapy, and some estimates project it could generate $15.1 billion in revenue by 2034 from pancreatic cancer alone. Some estimates put the number of U.S. patients diagnosed annually with metastatic pancreatic cancer at 55,000, with about 19,000 moving on to second-line treatment; assuming a roughly 30% net discount, the opportunity is nearly $3 billion a year. With a market cap of about $40 billion that has fallen since approval, the author says that at a 12% required rate of return and a forward price-to-sales ratio of 4 by 2031, revenue would need to reach $17.62 billion in 2032 to justify the current valuation. The author says they would seriously consider investing if the market cap falls by another $5 billion, citing clinical, regulatory and biotech volatility risks.

The article compares two lesser-known stocks, Revolution Medicines (RVMD) and Oruka Therapeutics (ORKA), which have both more than doubled this year and outpaced the Magnificent Seven. Revolution Medicines earned approval this year for Rasonque in metastatic pancreatic cancer, with a Phase 3 median overall survival of 13.2 months versus 6.7 months for cytotoxic chemotherapy, and some analysts project $20.8 billion in total peak revenue. Its average price target of $259.14 implies 35.7% upside, which the author considers too optimistic. Oruka has no approved medicine; its lead candidate ORKA-001, for plaque psoriasis, is in Phase 2a with encouraging results and could be dosed once or twice a year, while its $155 average target implies 95% upside. The author views Oruka as riskier than Revolution Medicines because ORKA-001 has not yet started Phase 3 trials.